2 U.S. lawmakers have disclosed 6 Valeant Pharmaceuticals International, Inc. (NYSE) trades under the STOCK Act — 3 buys and 3 sells between 2014 and 2015. Congress has been evenly split of VRX.
*Notional-weighted price return on lawmakers' disclosed buys of VRX, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2015-10-08 | David E. Price | SELL | $1K–$15K | — | — | — exit |
| 2015-01-26 | David E. Price | SELL | $1K–$15K | — | — | — exit |
| 2014-05-07 | Susan M Collins | SELL | $1K–$15K | — | — | — exit |
| 2014-03-11 | Susan M Collins | BUY | $1K–$15K | — | — | — |
| 2014-03-11 | Susan M Collins | BUY | $1K–$15K | — | — | — |
| 2014-03-11 | Susan M Collins | BUY | $1K–$15K | — | — | — |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
2 members of the U.S. House and Senate have disclosed Valeant Pharmaceuticals International, Inc. (NYSE) transactions under the STOCK Act — 3 purchases and 3 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a VRX purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Every VRX trade is marked to the latest close in the Return column; sells matched to a prior buy show a realized round-trip return.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded VRX and how it performed.